Related Experiment Video

Updated: Aug 29, 2026

Use of Viral Entry Assays and Molecular Docking Analysis for the Identification of Antiviral Candidates against Coxsackievirus A16
06:03

Use of Viral Entry Assays and Molecular Docking Analysis for the Identification of Antiviral Candidates against Coxsackievirus A16

Published on: July 15, 2019

Vaccination procedures against Coxsackievirus-induced heart disease

Andreas Henke1, Nadine Jarasch, Peter Wutzler

  • 1Institute of Virology and Antiviral Therapy, Medical Center at the Friedrich Schiller University Jena, Hans-Knöll-Strasse 2, D-07740 Jena, Germany. i6hean@rz.uni-jena.de

Expert Review of Vaccines
|January 9, 2004
PubMed

Insights

New vaccination strategies show promise in preventing Coxsackievirus B3 heart disease. An interferon-gamma-expressing recombinant Coxsackievirus variant effectively treated Coxsackievirus B3-induced myocarditis in mouse models.

Area of Science:

  • Virology
  • Immunology
  • Cardiology

Background:

  • Coxsackievirus B3 (CVB3), a picornavirus, is a primary cause of viral heart disease, leading to acute or chronic conditions.
  • Despite detailed molecular characterization of CVB3, effective clinical treatments for CVB3-induced heart disease have been limited until recently.
  • Existing research highlights the potential of vaccination strategies in preventing CVB3 infections.

Purpose of the Study:

  • To evaluate the efficacy of novel vaccination procedures against Coxsackievirus B3 infections.
  • To assess the effectiveness of a specific recombinant Coxsackievirus variant expressing interferon-gamma in treating CVB3-induced myocarditis.

Main Methods:

  • Utilized various murine (mouse) model systems to test vaccination procedures.
  • Administered a recombinant Coxsackievirus variant engineered to express interferon-gamma.
  • Focused on preventing and treating Coxsackievirus B3-induced myocarditis.

Main Results:

  • Both classic and newly developed vaccination methods demonstrated success in preventing Coxsackievirus B3 infections in murine models.
  • The application of the interferon-gamma-expressing recombinant Coxsackievirus variant proved effective against Coxsackievirus B3-induced myocarditis.

Conclusions:

  • Vaccination represents a viable strategy for preventing Coxsackievirus B3 infections and associated heart disease.
  • Recombinant viral variants, such as the interferon-gamma-expressing strain, offer a promising therapeutic approach for viral myocarditis.

More Related Videos

Gene Transfer for Ischemic Heart Failure in a Preclinical Model07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk05:15

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk

Published on: July 27, 2022

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...